{
  "id": "61f60735882a024a10000022",
  "type": "factoid",
  "question": "Which disease is treated with Risdiplam?",
  "ideal_answer": "Risdiplam is approved for spinal muscular atrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33098622",
    "http://www.ncbi.nlm.nih.gov/pubmed/33626251",
    "http://www.ncbi.nlm.nih.gov/pubmed/34888619",
    "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
    "http://www.ncbi.nlm.nih.gov/pubmed/33283185",
    "http://www.ncbi.nlm.nih.gov/pubmed/33231373",
    "http://www.ncbi.nlm.nih.gov/pubmed/33044711",
    "http://www.ncbi.nlm.nih.gov/pubmed/34183144",
    "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
    "http://www.ncbi.nlm.nih.gov/pubmed/34287987",
    "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
    "http://www.ncbi.nlm.nih.gov/pubmed/34368854",
    "http://www.ncbi.nlm.nih.gov/pubmed/34347881",
    "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
    "http://www.ncbi.nlm.nih.gov/pubmed/34283224",
    "http://www.ncbi.nlm.nih.gov/pubmed/30044619",
    "http://www.ncbi.nlm.nih.gov/pubmed/33458725",
    "http://www.ncbi.nlm.nih.gov/pubmed/34141064"
  ],
  "snippets": [
    {
      "text": "Furthermore, drug therapies including injectables such as onasemnogene abeparvovec-xioi (ZOLGENSMA\u00ae), nusinersen (SPINRAZA\u00ae), and an oral-solution, risdiplam (EVRYSDI\u2122), are medications that have been FDA-approved for the treatment of SMA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33098622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The United States' Food and Drug Administration's (FDA) approval of nusinersen, onasemnogene abeparvovec, and risdiplam for SMA has challenged existing treatment paradigms with multiple treatment options, a new natural history of the disease, and an emerging understanding of the importance of early and pre-symptomatic treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34183144",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam (Evrysdi\u2122) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33044711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SION: Combination therapy with onasemnogene and risdiplam in patients with SMA appears to be well-tolerated. Furth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34287987",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam is currently the only orally administered drug approved by the FDA for the treatment of SMA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam is the first and only oral medication to be approved to treat SMA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam was approved recently for the treatment of patients with SMA, aged\u00a0\u2265\u00a02\u00a0months in the United States, and is currently under Health Authority review in the EU.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33231373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Evaluation of ophthalmologic safety with focus on retinal safety in patients with spinal muscular atrophy (SMA) treated with risdiplam (EVRYSDI\u00ae), a survival of motor neuron 2 splicing modifier associated with retinal toxicity in monkeys.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33231373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam is the first approved small-molecule splicing modulator for the treatment of spinal muscular atrophy (SMA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam (Evrysdi) improves motor neuron function in patients with spinal muscular atrophy (SMA) and has been approved for the treatment of patients \u22652\u00a0months old. Ri",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34347881",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " small-molecule splicing modifier, risdiplam, was also approved for the treatment of SMA, highlighting small molecules as important warheads in the arsenal for regulating RNA splicing. The cellular ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam (Evrysdi\u2122) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33044711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ext. Very recently, an orally deliverable small molecule, risdiplam (Evrysdi\u2122), became the third approved therapy for SMA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33283185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "i\u2122 (risdiplam), recently approved for the treatment of SMA, and related compounds promote exon 7 inclusion to generate full-length SMN2 mRNA and increase SMN protein levels. SMN\u03947 ty",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34368854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy (SMA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " United States' Food and Drug Administration's (FDA) approval of nusinersen, onasemnogene abeparvovec, and risdiplam for SMA has challenged existing treatment paradigms with multiple treatment options, a new natural history of the disease, and an emerging understanding of the importance of early and pre-symptomatic treatment. The profo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34183144",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33098622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ently, the primary therapeutic strategy for SMA is to increase the level of SMN via correcting SMN2 splicing (nusinersen and risdiplam). How",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34888619",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s including injectables such as onasemnogene abeparvovec-xioi (ZOLGENSMA\u00ae), nusinersen (SPINRAZA\u00ae), and an oral-solution, risdiplam (EVRYSDI\u2122), are medications that have been FDA-approved for the treatment of SMA. This review discusses the current and ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Risdiplam for the Use of Spinal Muscular Atrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Risdiplam in Type 1 Spinal Muscular Atrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626251",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " These studies indicate that drugs such as risdiplam will be optimally therapeutic when given as early as possible after diagnosis and potentially will be required for the life of an SMA patient",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34368854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30044619",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "n monkeys. Risdiplam was approved recently for the treatment of patients with SMA, aged\u00a0\u2265\u00a02\u00a0months in the United States, and is currently under Health Authority review in the EU.METHODS: Subjects included patients with SMA aged 2\u00a0months-60\u00a0years enrolled in the FIREFISH, SUNFISH, and JEWELFISH clinical t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33231373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Additionally, we explore the recently FDA-approved small molecule regulator of RNA splicing, risdiplam, for treatment of spinal muscular atrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33458725",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In August 2020, Evrysdi\u2122 (risdiplam) received its first approval in the USA for the treatment of spinal muscular atrophy in patients 2\u00a0months of age and older.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33044711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Evaluation of ophthalmologic safety with focus on retinal safety in patients with spinal muscular atrophy (SMA) treated with risdiplam (EVRYSDI\u00ae), a survival of motor neuron 2 splicing modifier associated with retinal toxicity ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33231373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evrysdi\u2122 (risdiplam), recently approved for the treatment of SMA, and related compounds promote exon 7 inclusion to generate full-length SMN2 mRNA and increase SMN protein levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34368854",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "spinal muscular atrophy"
}